Tolman et al., J. Steroid. Biochem. Molec. Biol.,. vol. 60 (1997), pp. 303-309, “4-Methyl-3-oxo-4-aza-5α-androst-1-ene-17β-N-aryl-carboxamides: . . . ”. |
Bakshi et al., J. of Med. Chem., vol. 38 (1995), pp. 3189-3192, “4-Aza-3-oxo-5α-androst-1-ene-17β-N-aryl-carboxamides as dual inhibitors of human type 1 and type 2 steroid 5α-reductases . . . ”. |
Rasmusson et al., J. Med. Chem., vol. 29 (1986), pp. 2298-2315, “Azasteroids: Structure-activity relationships for inhibition of 5α-reductase and of androgen receptor binding”. |
Rasmusson et al., J. Med. Chem.,. vol. 27 (1984), pp. 1690-1701, “Azasteroids as inhibitors of rat prostatic 5α-reductase”. |
Kurata et al., Chem. Pharm. Bull., vol. 44 (1996), pp. 115-121, “Synthesis and testosterone 5α-reductase-inhibitory activity of 4-aza-5α-androstane-17-carboxamide compound with an aromatic moiety in the C-17 carbamoyl group”. |
Zheng et al., Chem. Abstracts, vol. 122 (1995), pp. 979, “Synthesis of N-substituted-4-methyl-3-oxo-4-aza-5α-androstane-17β-carboxamide compounds”. |
Mellin et al., J. Steroid Biochem. Molec. Biol., vol. 44 (1993), pp. 121-131, “Azasteroids as inhibitors of testosterone 5α-reductase mammalian skin”. |
Liang et al. Endocrinology , vol. 117 (1985), pp. 571-579, “Species differences in prostatic steroid 5α-reductases in rat, dog, and human”. |
Bakshi et al., MEDI, No. 011, “N-Phenyl-3-oxo-4-aza-5α-androst-1-en-17β-carboxamides as inhibitors of both human type 1 and type 2 5α-reductase”. |
Tolman et al., “4-Methyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-N-aryl-carboxamide: An approach to combined androgen blockade”; in press, expected to publish in Mar. 1996 issue of J. Steroid Biochem & Molec. Bio. |
Tolman et al., 5th Int'l Congress Hormones & Cancer Program and Abstract, Quebec City, Sep. 16-20, 1995, p. 92, abstract No. 48, “4-Methyl-4-azasteroid 17β-(N-aryl-substituted)carboxamides: Potent antiandrogenic activity with 5α-reductase inhibition”. |